The investigators plan to conduct a two arm study, to compare failure rates in the central
nervous system (CNS) and genital compartment in virologically fully suppressed patients
continuing a highly active antiretroviral therapy (HAART) versus patients switching to
ritonavir boosted lopinavir (Kaletra®) HIV-monotherapy. The study is composed of two phases
of 48 weeks duration.
In addition, neuropsychological tests (Color trial test A 1 and 2; Grooved pegboard; EWIA
Digit Symbol form) and evaluation of side effects will be performed.
Phase:
Phase 4
Details
Lead Sponsor:
Cantonal Hospital of St. Gallen
Collaborators:
Swiss HIV Cohort Study Swiss National Science Foundation